Ioxilan

Ioxilan
Systematic (IUPAC) name

1-N-(2,3-dihydroxypropyl)-5-[N-(2,3-dihydroxypropyl)acetamido]-3-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	US: B (No risk in non-human studies)
Routes of administration	intravenously
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	N/A
Protein binding	negligible
Biological half-life	2 hours
Excretion	Mostly renal
Identifiers
CAS Number	107793-72-6^N
ATC code	V08AB12 (WHO)
PubChem	CID 3743
ChemSpider	3612^Y
UNII	A4YJ7J11TG^Y
KEGG	D02161^Y
ChEMBL	CHEMBL1201075^N
Chemical data
Formula	C₁₈H₂₄I₃N₃O₈
Molar mass	791.112
SMILES O=C(N(c1c(I)c(c(I)c(c1I)C(=O)NCCO)C(=O)NCC(O)CO)CC(O)CO)C
InChI InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)^Y Key:UUMLTINZBQPNGF-UHFFFAOYSA-N^Y
^NY (what is this?) (verify)

Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.

Contrast media (V08)

X-ray and CT

Iodinated,
Water soluble

Nephrotropic, high osmolar	Diatrizoic acid^# Metrizoic acid Iodamide Iotalamic acid Ioxitalamic acid Ioglicic acid Acetrizoic acid Iocarmic acid Methiodal Diodone

Nephrotropic, low osmolar	Metrizamide Iohexol^# Ioxaglic acid Iopamidol Iopromide Iotrolan Ioversol Iopentol Iodixanol Iomeprol Iobitridol Ioxilan

Hepatotropic	Iodoxamic acid Iotroxic acid Ioglycamic acid Adipiodone Iobenzamic acid Iopanoic acid Iocetamic acid Sodium iopodate Tyropanoic acid Calcium iopodate

Iodinated,
Water insoluble

Non-iodinated

Barium sulfate^#

MRI

Paramagnetic	Gadolinium-based: Gadobenic acid Gadobutrol Gadodiamide Gadofosveset Gadolinium Gadopentetic acid Gadoteric acid Gadoteridol Gadoversetamide Gadoxetic acid Other: Ferric ammonium citrate Mangafodipir

Superparamagnetic	Ferumoxsil Ferristene Iron oxide, nanoparticles

Other	Perflubron

Ultrasound

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Saturday, April 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.